|
KMID : 1120220210120040264
|
|
Osong Public Health and Research Perspectives
2021 Volume.12 No. 4 p.264 ~ p.268
|
|
|
COVID-19 vaccine safety monitoring in the Republic of Korea: February 26, 2021 to April 30, 2021
|
|
Oh Hyun-Kyung
Kim Eun-Kyeong
Hwang In-Sob
Kim Tae-Eun
Lee Yeon-Kyeong
Lee Eun-Ju
Lee Yeon-Kyeng
|
|
|
Abstract
|
|
|
Objectives: On February 26, 2021, coronavirus disease 2019 (COVID-19) vaccination was started for high-priority groups based on the recommendation of the Advisory Committee on Immunization Practices with 2 available COVID-19 vaccines (AstraZeneca and Pfizer-BioNTech) in Korea. This report provides a summary of adverse events following COVID-19 vaccination as of April 30, 2021.
Methods: Adverse events following immunization are notifiable by medical doctors to the Korea Immunization Management System (KIMS) under the national surveillance system. We analyzed all adverse events reports following COVID-19 vaccination to the KIMS from February 26 to April 30, 2021.
Results: In total, 16,196 adverse events following 3,586,814 administered doses of COVID-19 vaccines were reported in approximately 2 months (February 26 to April 30, 2021). Of these, 15,658 (96.7%) were non-serious adverse events, and 538 (3.3%) were serious adverse events, including 73 (0.5%) deaths. The majority of adverse events (n=13,063, 80.7%) were observed in women, and the most frequently reported adverse events were myalgia (52.2%), fever (44.9%), and headache (34.9%). Of the 73 deaths following the COVID-19 vaccination, none were related to the vaccines.
Conclusion: By April 30, 3.6 million doses of the COVID 19 vaccine had been given in Korea, and the overwhelming majority of reports were for non-serious events. The Korea Disease Control and Prevention Agency continues to monitor the safety of COVID-19 vaccination.
|
|
|
KEYWORD
|
|
|
Adverse event, COVID-19, Safety, Vaccines
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|